CAR-T therapies have revolutionized blood cancer treatment, but traditional ex vivo manufacturing remains costly and time-consuming. Next-generation in vivo CAR-T is set to change the game, driven by two delivery platforms: LVV (viral) and LNP (non-viral). Join our online webinar to explore how LVV and mRNA-tLNP are accelerating the industrialization of in vivo CAR-T therapies.
Lentiviral Vector Process Development for In Vivo CAR-T: Key Points and Core Challenges
Dr. Chunling Xuan, Director. LVV PD, ProBio
mRNA-tLNP for In Vivo CAR-T: Challenges and Solutions
Dr. Jiang Xu, Head of LNP formulation, ProBio
Register Now
info@wilam.comAn initiative ofBioMelbourne NetworkLevel 6, HWT Tower40 City RoadSouthbank, VIC 3006
Wilam means home in the Woi-wurrung language of the Wurundjeri People of the Kulin Nation, the Traditional Owners of the lands on which we are based.We respectfully acknowledge the Traditional Custodians of the unceded lands and waters of Victoria, the Bunurong, Eastern Maar, Gunaikurnai, Wadawurrung and Wurundjeri Woi-wurrung peoples, on which we live and work. We pay respect to their Elders past and present. We acknowledge the significant contribution that they and other Aboriginal and Torres Strait Islander people have made and continue to make to the research and knowledge systems that inform our community and our sector. We acknowledge that Aboriginal and Torres Strait Islander people continue to live in a spiritual and sacred relationship with this country and recognise our responsibility to continue to work towards reconciliation.